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CalDAG-GEFI (CDGI) is a protein highly enriched in the striatum, particularly in the principal spiny projection
neurons (SPNs). CDGI is strongly down-regulated in two hyperkinetic conditions related to striatal dysfunction:
Huntington's disease and levodopa-induced dyskinesia in Parkinson's disease. We demonstrate that genetic
deletion of CDGI in mice disrupts dendritic, but not somatic, M1 muscarinic receptors (M1Rs) signaling in in
direct pathway SPNs. Loss of CDGI reduced temporal integration of excitatory postsynaptic potentials at den
dritic glutamatergic synapses and impaired the induction of activity-dependent long-term potentiation. CDGI
deletion selectively increased psychostimulant-induced repetitive behaviors, disrupted sequence learning, and
eliminated M1R blockade of cocaine self-administration. These findings place CDGI as a major, but previously
unrecognized, mediator of cholinergic signaling in the striatum. The effects of CDGI deletion on the selfadministration of drugs of abuse and its marked alterations in hyperkinetic extrapyramidal disorders highlight
CDGI's therapeutic potential.

* Corresponding author at: McGovern Institute for Brain Research and Dept. of Brain and Cognitive Sciences, MIT, Cambridge, MA 02139, USA.
E-mail address: graybiel@mit.edu (A.M. Graybiel).
1
Co-first authors
2
Lead Contact.
https://doi.org/10.1016/j.nbd.2021.105473
Received 5 May 2021; Received in revised form 21 July 2021; Accepted 2 August 2021
Available online 8 August 2021
0969-9961/© 2021 The Authors.
Published by Elsevier Inc.
This is
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

an

open

access

article

under

the

CC

BY-NC-ND

license

J.R. Crittenden et al.

Neurobiology of Disease 158 (2021) 105473

1. Introduction

2. Results

CalDAG-GEFI (CDGI) is a striatum-enriched signaling molecule that
is allosterically activated by Ca2+ to stimulate the small GTPase Rap1
(Crittenden et al., 2004; Kawasaki et al., 1998; Toki et al., 2001).
Working through Rap1, CDGI has been shown to modulate multiple
pathways in non-neuronal cell types in vivo, including integrin-adhesion
to surface ligands, vesicle release, and activity of the mitogen-activated
kinases (MAPKs), extracellular signal-activated kinase (ERK) and p38MAPK (Crittenden et al., 2004; Crittenden et al., 2019; Guo et al.,
2001; ; Kawasaki et al., 1998; Stefanini and Bergmeier, 2010; ). Given
that Rap1 signaling cascades are linked to a variety of downstream ef
fectors that can impact ion channels, transcription factors, cell adhesion,
cell death, neuroplasticity and more (Impey et al., 1999; York et al.,
1998; Kosuru and Chrzanowska, 2020; Huang et al., 2004; Takeda and
Ichijo, 2002), CDGI is in a position, within select cells of expression, to
modulate a wide array of functions.
One potential clue to the upstream signaling that activates neuronal
CDGI is its robust expression in spiny projection neurons (SPNs) of the
matrix compartment of the striatum (Kawasaki et al., 1998). The matrix
compartment is highly enriched with molecules related to cholinergic
signaling, of which choline acetyltransferase and acetylcholinesterase
are examples (Graybiel et al., 1986; Graybiel and Ragsdale, 1978).
Moreover, in PC12 cell cultures, M1 muscarinic receptors (M1Rs) signal
through CDGI, Rap1 and ERK (Guo et al., 2001). This further link to the
cholinergic system raised the question of whether this signaling would
hold for the SPNs. Like CDGI (Toki et al., 2001), M1Rs are expressed by
both indirect pathway SPNs (iSPNs) and direct pathway SPNs (dSPNs) in
the matrix compartment (Bernard et al., 1992; Hersch et al., 1994; Yan
et al., 2001).
Strong further clues about the neurological functions of CDGI come
from work related to clinical signs of extrapyramidal disorders. CDGI is
early on and markedly down-regulated in the striatum in Huntington's
disease (HD) and in rodent HD models (Crittenden et al., 2010; Desplats
et al., 2006; Kuhn et al., 2007; Luthi-Carter et al., 2002). In a mimic of
this situation, knock-down of CDGI in cultured striatal brain slices
expressing a mutant fragment of huntingtin was found to rescue the HD
model cellular phenotype in that it fully prevented the neuro
degeneration that is normally caused by mutant huntingtin (Crittenden
et al., 2010). CDGI was also found to be severely down-regulated in the
6-hydroxydopamine lesion model of Parkinson's disease in response to
levodopa treatment, and the CDGI depletion was positively correlated
with the severity of levodopa-induced dyskinesia (LID) (Crittenden
et al., 2009). Thus, in two hyperkinetic disorders with strong striatal
links—HD and LID—CDGI appears to be strongly dysregulated. In both
of these disorders, hypoactivity of matrix iSPNs is thought to be one
factor causally related to the behavioral deficits (Albin et al., 1989;
Alcacer et al., 2017).
To test directly the striatal function of CDGI, we generated two lines
of mice with deletions in the gene encoding CDGI: one in which the
deletion was constitutive and global, and another in which deletion was
limited to postnatal striatum. The constitutive CDGI knockout line was
crossed with mice in which either iSPNs or dSPNs expressed a fluores
cent marker (Gong et al., 2003). In these mice, the impact of CDGI
deletion was examined in identified dSPNs or iSPNs. We found that
CDGI has selective effects on dendritic M1R function in iSPNs, and that it
is required for long-term synaptic potentiation in these cells. We further
found that deletion of CDGI produces deficits in motor sequence
learning and abnormalities in responses to psychomotor stimulant
treatment, and that the deletion of CDGI prevents the capacity for M1R
agonist treatment to block self-administration of cocaine. We propose
CDGI to be a major modulator of striatal function by virtue of its
essential position in M1R cholinergic receptor signaling.

2.1. CDGI deletion did not produce generalized brain pathology or
baseline behavioral deficits
To achieve constitutive knockout of CDGI, we engineered a deletion
near the 5′ end of CDGI (aka RasGRP2) that resulted in a nonsense
mutation (stop codon) (Fig. S1A). In brain tissue from mice that were
homozygous for this mutation, the deleted exons were not detected in
mRNA assays, and CDGI protein expression was lost (Figs. 1A-F and S1BD,G). Expression of CalDAG-GEFII (aka RasGRP) mRNA was unchanged
in CDGI knockout mice (Fig. S1H). CDGI is broadly expressed in the
brain during prenatal development and, in the adult, is expressed at
lower levels in some brain regions outside the striatum, including the
cerebral cortex (Fig. 1A) (Crittenden et al., 2010; Kawasaki et al., 1998;
Toki et al., 2001). To examine more specifically the function of striatal
CDGI in the adult, we generated mice in which CDGI was floxed
(Fig. S1A) and crossed them to D1-YAC Cre mice in which Cre recom
binase was expressed after birth in the majority of SPNs (Lemberger
et al., 2007) (Figs. 1G and S1E,F). The D1-YAC Cre line is reported to
drive postnatal deletion in most SPNs that express the D1 dopamine
(DA) receptor, and many that express the D2 receptor, with lesser ac
tivity in the cerebral cortex, cerebellum and other brain regions (Lem
berger et al., 2007; Monory et al., 2007). Consistent with this account,
we found that CDGIflox/floxCre(+) mice had normal CDGI expression in
the striatum and olfactory tubercle at birth that gradually declined so
that all striatal expression appeared to be gone by adulthood, but with
maintained expression in the cerebral cortex (Figs. 1G and S1E,F).
Both constitutive and conditional CDGI knockout mice were fertile
and displayed no obvious behavioral changes or abnormalities in brain
structure. Neural exams of the constitutive CDGI knockouts showed
normal gross brain anatomy (Fig. S2A), normal DA receptor binding in
the striatum (Fig. S2B and Table S1), normal expression of striatal
protein markers (Fig. S2C), normal transcriptome-wide striatal mRNA
expression levels (Table S2) and normal levels of total striatal amino
acids and biogenic amines (Tables S3 and S4). There were no differences
between CDGI knockouts and sibling controls in adult weight, daily
chow consumption (Fig. S2D), rotarod motor coordination (Fig. S2E),
open-field behavior (Fig. S2F), olfactory acuity (Fig. S2G), responses on
a SHIRPA neurological exam (Rogers et al., 1997) (Table S5), learned
helplessness (Fig. S2H), marble-burying behavior (Fig. S2I), cue- or
context-paired fear conditioning (Fig. S2J,K) or social recognition
memory (Fig. S2L). Automated home-cage monitoring of behaviors
showed no detectable differences between wildtype and CDGI knockout
mice (Fig. S2M).
2.2. CDGI was not necessary for M1R modulation of SPN somatic
excitability
To characterize the effects of CDGI deletion in identified iSPNs and
dSPNs, ex vivo parasagittal brain slices were prepared from constitutive
CDGI knockout mice crossed with either Drd2-EGFP or Drd1-tdTomato
reporter lines, and patch clamp recordings were made from visually
identified neurons (Figs. 2A,B). Recordings were made from the dorso
lateral striatum where CDGI-poor striosomes were scarce (Fig. 1E)
(Crittenden et al., 2016). In recordings from wildtype SPNs, M1R acti
vation promotes closing of Kv7 (KCNQ) potassium channels in the per
isomatic region by depleting the plasma membrane lipid,
phosphatidylinositol 4,5-bisphosphate (PIP2). Closing of Kv7 K+ chan
nels increases somatic membrane resistance near spike threshold,
resulting in increased somatic excitability (Shen et al., 2005). To
determine whether CDGI participates in this modulation, we measured
the spiking evoked by somatic current injection and its modulation by
bath application of the muscarinic receptor agonist, oxotremorine-M
(Oxo-M, 10 μM), using whole-cell recordings of iSPNs and dSPNs in ex
vivo slices from CDGI knockout and wildtype mice. Consistent with
2
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Fig. 1. Generation of CDGI global knockout and conditional knockout mice. (A) CDGI immunostaining in sagittal section through mouse brain showing expression in
direct and indirect striatal output projections from the caudoputamen (CP) to, respectively, the substantia nigra pars reticulata (SNpr) and the external globus
pallidus (GP). (B, C) CDGI immunofluorescence (red) shows co-expression in cell soma (yellow) with green fluorescent protein (EGFP) in transgenic mice that express
EGFP in D1 direct pathway (B) or D2 indirect pathway (C) neurons. (D, E) CDGI (red) enriched in matrix relative to striosomes, shown in transverse mouse striatal
section co-labeled for the striosomal marker CalDAG-GEFII (CDGII, green, shown in (D)). (F) CDGI immunoreactivity (black) in control (top) and global knockout
(bottom) coronal mouse brain hemisection. (G) CDGI expression is lost postnatally in conditional CDGIflox/flox mice that carry a D1-yeast artificial chromosome (YAC)
driving Cre expression (bottom) but not in CDGIflox/flox control mice (top). (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)

previous observations (Shen et al., 2005), in both iSPNs and dSPNs from
wildtype mice, Oxo-M produced a leftward shift in the relationship be
tween intrasomatic current injection and spiking: less current was
required to produce the same level of spiking across the full range of
spiking rates (Figs. 2C,D,F,G). This modulation was intact in CDGIdeficient iSPNs and dSPNs (Figs. 2C,E,F,H).

2.4. CDGI mediated the M1R modulation of long-term potentiation in
iSPNs
Given its dendritic function, we asked whether CDGI signaling might
also be involved in long-term synaptic plasticity (Crittenden et al.,
2019). A transient suppression of M1R signaling has been implicated in
the induction of long-term depression (LTD) in SPNs (Wang et al., 2006),
but its role in long-term synaptic potentiation (LTP) of glutamatergic
synapses is controversial. An early report suggested that M1R signaling
was necessary for LTP induction at corticostriatal synapses in both
classes of SPN (Calabresi et al., 1999). However, recent work has shown
that in dSPNs dendritic M4 muscarinic receptors blunt LTP induction
(Hernandez-Flores et al., 2015; Shen et al., 2015), raising doubts about
the potential role of M1Rs in dSPNs. To address this issue, we first
recorded synaptic responses in wildtype iSPNs using a K+-based internal
solution before and after four bouts of high frequency stimulation (HFS;
100 Hz for 1 s) of glutamatergic axons with coincident intracellular
depolarizing current pulse (1–2 nA for 1 s). This protocol induced a
robust LTP in iSPNs that was blocked by the muscarinic receptor
antagonist, scopolamine (10 μM) (Fig. 3A). In dSPNs, this HFS protocol
did not produce LTP with normal extracellular Mg2+ (1 mM) (Fig. 3C).
However, when the extracellular Mg2+ concentration was lowered to
nominally zero, this protocol did induce LTP in dSPNs (Fig. 3C) (Cala
bresi et al., 1992a). However, in contrast to the LTP in iSPNs, antago
nizing muscarinic receptors did not significantly affect the LTP in dSPNs
(Fig. 3D). Next, we repeated these experiments in CDGI knockout mice.
In dSPNs lacking CDGI, LTP induction was not significantly different
from that seen in wildtype dSPNs (Fig. 3D). By contrast, in iSPNs lacking
CDGI, LTP induction was significantly reduced, suggesting that CDGI
signaling was critical to the dendritic signaling underlying LTP (Fig. 3B).

2.3. CDGI was necessary for M1R-mediated modulation of iSPN dendritic
excitability
In iSPNs (but not in dSPNs), M1R activation enhances dendritic
excitability and the summation of excitatory post-synaptic potentials
(EPSPs). This effect is accomplished by decreasing the opening of den
dritic Kir2.3 potassium channels (Shen et al., 2007). We tested for the
involvement of CDGI in this modulation of dendritic excitability by
asking whether M1R signaling enhanced temporal summation in iSPNs
from CDGI knockout mice. We stimulated corticostriatal glutamatergic
axons (five pulses at 40 Hz) while monitoring somatic voltage in whole
cell recordings of iSPNs (Fig. 2I). As expected, in iSPNs of wildtype mice,
bath application of Oxo-M (10 μM) significantly increased dendritic
EPSP summation, as estimated by the ratio of the fifth to the first EPSP
amplitudes (EPSP5/EPSP1, Fig. 2J), and slowed the EPSP decay kinetics
(Fig. 2K). The Oxo-M modulation was prevented by application of the
M1R-specific antagonist VU0255035 (5 μM) (Sheffler et al., 2009)
(Figs. 2I-K). In iSPNs from CDGI knockouts, by contrast, Oxo-M did not
significantly affect the dendritic integration of glutamatergic EPSPs
(Figs. 2I-K). These findings demonstrate that CDGI is necessary for the
dendritic M1R-mediated modulation of Kir2 K+ channels in iSPNs, in
contrast to its lack of influence on the M1R modulation of somatic
excitability.
3
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Fig. 2. CDGI mediates the M1R modulation
of dendritic excitability but not the M1R
modulation of somatic excitability. (A, B)
Sagittal sections through the brains of CDGI
knockout mice in which the direct pathway
was visualized (red) in D1-tdTomato x CDGI
knockout mice (A) and the indirect pathway
was visualized (green) in D2-EGFP x CDGI
knockout mice (B). (C) Sample somatic
voltage changes evoked by 120 pA current
injections in iSPNs from wildtype (WT, blue)
and CDGI knockout (KO, red) mice before
and after bath application of Oxo-M (10 μM).
(D, E) Current-response curves of iSPNs from
WT (D, n = 5 cells from 3 mice) and CDGI KO
(E, n = 7 cells from 4 mice) mice. Somatic
excitability of iSPNs was similarly enhanced
by Oxo-M in WT and CDGI KO mice. Error
bars show standard error of the mean (SEM).
(F) Sample somatic recordings in response to
140 pA current injections in dSPNs from WT
(blue) and CDGI KO (red) mice before and
after bath application of Oxo-M (10 μM). (G,
H) Current-response curves of dSPNs from
WT (G, n = 5 cells from 3 mice) and CDGI KO
(H, n = 7 cells from 3 mice) mice. (I) Trains
of five EPSPs were evoked by stimulation of
glutamatergic afferent fibers at 40 Hz. OxoM (10 μM) increased EPSP summation in
iSPNs of WT mice, but not in CDGI KO mice
or when M1Rs were blocked by M1R antag
onist VU0255035 (5 μM) in WT mice. (J) Box
plot showing the effect of Oxo-M on synaptic
summation. The EPSP5/EPSP1 ratio was
increased by Oxo-M in iSPNs of WT mice (p
= 0.002, Wilcoxon test; n = 10 cells from 4
mice), but not in iSPNs of CDGI-KO mice (p
= 0.25, n = 9 cells from 4 mice) or in iSPNs
of WT mice in the presence of VU0255035
(p = 0.69, n = 6 cells from 3 mice). (K) Box
plot showing the effect of Oxo-M on the ki
netics of synaptic response. The decay time
constant of EPSP5 was significantly
increased by Oxo-M in iSPNs of WT mice (p
= 0.002), but not when CDGI was genetically
deleted (p = 0.65) or when M1R was phar
macologically blocked (p = 0.84). (For
interpretation of the references to colour in
this figure legend, the reader is referred to
the web version of this article.)

An alternative interpretation of these results is that the failure to induce
potentiation in iSPNs from CDGI knockout mice was due to saturation of
the LTP mechanism. If this were the case, then low frequency stimula
tion (LFS) of glutamatergic synapses should induce depotentiation
(Picconi et al., 2003) in iSPNs from CDGI knockout mice, but not in
wildtype iSPNs. However, the responses to LFS were indistinguishable in
iSPNs from wildtype and CDGI knockout mice, arguing against this
alternative interpretation (Fig. S3A).

To ensure that CDGI deletion did not alter the release of acetylcho
line (ACh), we used an optical approach that took advantage of a
recently developed genetically encoded fluorescent sensor for
ACh—iAChSnFR (Borden et al., 2020). iAChSnFR was virally expressed
in the dorsolateral striatum of wildtype and CDGI knockout mice. Three
to five weeks later, ex vivo parasagittal slices were examined using twophoton laser scanning microscopy and time-series imaging (Fig. 3E).
ACh release was evoked with a train of 20 electrical stimuli (1 ms × 50
4
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Fig. 3. M1R-CDGI signaling is required for full in
duction of LTP in iSPNs, but not in dSPNs. (A) In
normal ACSF (1 mM Mg2+), LTP was induced in iSPNs
from wildtype (WT) mice (n = 9 cells from 7 mice) by
HFS (100 Hz for 1 s) paired with current injection
(1–2 nA, 1 s), which was repeated four times with 20 s
intervals. The LTP induction protocol is indicated by a
grey bar. The LTP was blocked by muscarinic antag
onist scopolamine (sco, 10 μM, n = 6 cells from 4
mice). Data points are mean ± SEM. Samples of
averaged EPSP traces before and 30 min after induc
tion are shown at the top. Scale bars, 5 mV × 20 ms.
(B) In CDGI knockout (KO) mice (n = 6 cells from 4
mice), LTP in iSPNs was impaired. (C) In normal
ACSF (1 mM Mg2+), LTP could not be induced in
dSPNs of WT mice (n = 7 cells from 4 mice). In
nominal 0 mM Mg2+ solution, a robust LTP was
induced in dSPNs from WT mice (n = 6 cells from 3
mice) by three trains of HFS (100 Hz for 1 s) with 20 s
interval (indicated by a grey bar). (D) Genetic dele
tion of CDGI or scopolamine did not affect LTP in
dSPNs (both n = 6 cells from 3 mice). (E) Sample
image showing expression of ACh sensor iAChSnFR
by SPNs. ROI is indicated by the dashed circle. Scale
bar = 20 μm. (F) Sample traces of ACh signal (quan
tified as ΔF/(Fsat − F0)) in response to a train of 20
electrical stimulations (20 Hz and 2 Hz, indicated
respectively by dark and light grey bars) in acute
slices from WT (blue) and CDGI KO (red) mice. Scale
bars, 0.1ΔF/(Fsat − F0) x 10 s. (G) Box plot showing
amplitudes of ΔF/(Fsat − F0) in WT and CDGI KO mice
with two stimulation paradigms. ns, not statistically
different; Mann-Whitney test. (For interpretation of
the references to colour in this figure legend, the
reader is referred to the web version of this article.)

μA, at 2 Hz or 20 Hz) delivered through a stimulating electrode placed
near (~200 μm) the imaged region. In slices from both wildtype and

(Calabresi et al., 1992b; Gerdeman et al., 2002). LTD induction was
intact in CDGI knockout mice (Fig. S3B).

CDGI knockout mice, the iAChSnFR signal rose rapidly with stimulus
onset, decayed when the stimulation ended and returned to baseline
within about a minute (Fig. 3F). The iAChSnFR signal was indistin
guishable in wildtype and CDGI knockout slices (Figs. 3F,G), strongly
suggesting that CDGI had not influenced plasticity indirectly by altering
ACh release.
To ensure that other forms of synaptic plasticity were intact,
endocannabinoid-mediated long-term synaptic depression (eCb-LTD)
was examined in ex vivo brain slices using standard approaches

2.5. CDGI deletion altered network control of DA release in the striatum
Given the tie between the muscarinic cholinergic system and both
DA and CDGI in the striatum (Gerber et al., 2001; Shin et al., 2015;
Zhang et al., 2002), we examined whether CDGI deletion affected DA
release in the striatum. We reasoned that the suppression of iSPN
excitability induced by CDGI deletion could trigger compensatory
network mechanisms aimed at fulfilling the functional role of iSPNs in
5
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movement control. One way in which iSPN excitability could be restored
would be by reducing striatal DA release (Klaus et al., 2019; Stoof and
Kebabian, 1981). If this line of reasoning were correct, in vivo basal DA
levels should be reduced, whereas they should be unchanged in ex vivo
preparations in which DA terminal excitability has been dissociated
from the network mechanisms controlling DA release.
To test this hypothesis, striatal DA release was measured in ex vivo
and in in vivo preparations. First, fast-scan cyclic voltammetry in ex vivo
striatal slice preparations (Figs. 4A-C) was used to measure DA release
evoked in response to single stimuli and trains of stimuli designed to
emulate phasic firing (4 and 10 pulses of 100 Hz). The release with
single and multiple stimuli was not significantly different in striatal
sections from CDGI knockout and wildtype control mice (Figs. 4A,B).
Moreover, paired pulse depression was not different from controls in
CDGI knockouts at inter-pulse intervals ranging from 1 to 60 s (Fig. 4C).
Thus, evoked DA release appeared to be normal at our level of detection
in the CDGI knockout, suggesting that the dopaminergic terminals did
not have intrinsic abnormalities. This finding is consistent with the fact
that CDGI expression in mice has not been observed in dopaminergic
neurons themselves (Kawasaki et al., 1998). Next, in awake, resting
CDGI knockouts and controls, extracellular DA levels in the striatum
were assessed using microdialysis. Resting extracellular DA levels in
CDGI knockout mice were half those in wildtype mice (Fig. 4D). Total
DA content and catechol-O-methyl transferase (COMT) activity were
similar in CDGI knockouts and controls (Fig. S4). Thus, the CDGI
knockouts had reduced levels of extracellular DA in tests in in vivo
preparations, but not in ex vivo preparations, suggesting that striatal
dysfunction resulting from the deletion of CDGI triggered network-level
changes that lowered DA release in the striatum.

striatal learning mechanisms from putative allocentric, ‘declarative’
hippocampal learning mechanisms (Packard and McGaugh, 1996). We
trained the constitutive CDGI deletion mutants and sibling controls to
learn how to navigate a maze for a food reward using self-referential,
egocentric cues (e.g., left-right). Wildtype mice rapidly learned an
egocentric T-maze task, but CDGI knockout mice were significantly
slower (Fig. 5A). In a reversal learning test and in an allocentric maze
task, however, the performance of CDGI knockout and wildtype mice
was indistinguishable (Figs. 5B,C). This pattern of results suggests that
the CDGI deletion had selective effects and that the temporal dynamics
of the maze learning were altered (Schreiweis et al., 2014).
Another type of motor learning that involves the striatum is learning
how to link a sequence of motor acts together to form a behavioral
repertoire (Barnes et al., 2005; Graybiel, 1998; Graybiel and Grafton,
2015; Martiros et al., 2018). To assess this form of learning, we used a
peg-wheel running assay (Kitsukawa et al., 2011; Nakamura et al.,
2017). In this task, the arrangement of the wheel's left and right footstep
pegs can be changed to test the ability to learn different running patterns
(Fig. 5D). Learning was assessed by computing the variance in the timing
of paw-placement on the pegs. The CDGI knockout mice did not differ
significantly from wildtypes in performance of complex peg-running
tasks (Fig. 5E). However, when the whiskers of the mice were clipped
before they were tested, forcing mice to rely upon proprioceptive cues
(Kincaid and Wilson, 1996; Moussa et al., 2011; Packard and McGaugh,
1996), the CDGI knockout mice again learned the task more slowly
(Fig. 5E and Fig. S5). Thus, mice lacking CDGI have a deficit in learning
sequential motor behaviors when critical sensory cues were not
available.

2.6. CDGI deletion impaired striatum-based learning

2.7. CDGI deletion enhanced behavioral responses to psychomotor
stimulants

Striatal activity is known to be important in learning and plasticity,
and it was thus natural to test different forms of learning. Moreover,
striatal M1R signaling has been implicated in the acquisition and
reversal of several forms of response learning (Lv et al., 2017; McCool
et al., 2008; Tzavos et al., 2004). Given these ties, we turned to three
different behavioral tests. First, we adopted the classic cross-maze task
developed to discriminate putative habit-based, procedural, egocentric

Given its rich innervation by dopamine-containing axons, striatal
function is profoundly affected by psychomotor stimulants, such as
amphetamine and cocaine. Psychomotor stimulants differentially affect
immediate-early gene (IEG) expression in striosomes relative to their
expression in the matrix, scored as a ratio (Crittenden and Graybiel,
2016; Graybiel, 1998, 2008; Saka et al., 2004). This activation depends
in part upon cholinergic interneurons and M1R signaling, as ablation of
Fig. 4. CDGI knockout mice have normal evoked DA
release but diminished extracellular DA in vivo. (A)
Examples (left) and averages (right) of DA release in
response to a single pulse (1p) in wildtype (WT, blue)
and CDGI knockout (KO, red) mice. (B) DA release in
response to a single pulse (1p) or train stimuli (4 or 10
paired stimuli at 100 Hz, 4p and 10p, respectively)
was not significantly different between WT and KO
mice. n = 14 slices for 1p, n = 8 slices for 4p and for
10p with slices taken from 5 mice per genotype per
experiment. By two-tailed t-test, p = 0.58 for 1p; p =
0.57 for normalized 4p; p = 0.19 for normalized 10p.
(C) Paired-pulse stimulation showed equivalent
depression of evoked DA release between genotypes
(p > 0.05, Student's two-tailed t-test, n = 7 slices from
each of 5 mice per genotype). (D) In vivo microdialysis
in the dorsal striatum showed reduced DA and
DOPAC and a trend for reduced HVA in KO mice,
relative to WT mice. P values were calculated by
Student's unpaired, two-tailed t-tests between average
values. Error bars show SEM. (For interpretation of
the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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Fig. 5. CDGI knockout mice exhibit deficits in striatal learning. (A) In an egocentric T-maze task, CDGI knockout (KO, red) mice learned more slowly than wildtype
(WT, blue) mice. p < 0.05 by ANOVA; **p = 0.009 on day 6; **p = 0.006 on day 7; *p = 0.04 on day 8 by unpaired, two-tailed Student's t-test. Error bars show SEM.
(B) Following the acquisition of the egocentric learning task (A), the rewarded arm was switched to test reversal learning, for which WT and CDGI KO mice showed
equivalent acquisition. p > 0.05 on all days by unpaired, two-tailed Student's t-test. (C) CDGI KO mice learned to navigate an allocentric, hippocampus-dependent, Tmaze at the same rate as sibling controls. Genotype effect: p = 0.588, session effect: p < 0.001, genotype-by-session interaction effect: p = 0.713, ANOVA. (D)
Illustration of the motor sequence task on a peg-wheel. (E) Mice were trained in a running wheel with unevenly spaced foot-rungs and learning was measured as a
reduction in the variance of paw placement on a designated rung. Intact KO and WT mice learned at equivalent rates; after whisker-cutting, KO mice showed delayed
re-acquisition. **p = 0.01 and *p = 0.02 by unpaired, two-tailed Student's t-test between genotypes. Numbers of mice tested are shown in panel keys. (For inter
pretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

cholinergic interneurons or deletion of M1Rs increases the stimulatory
effects of amphetamine (Gerber et al., 2001; Xu et al., 2015). Such
treatments also disrupt the pattern of IEG expression and the levels of
confined, repetitive behavior (stereotypy) induced by DA receptor ag
onists (Aliane et al., 2011; Saka et al., 2002). We treated wildtypes and
CDGI knockouts with high and intermediate doses of amphetamine that
are known to induce stereotypy. Mice with global deletion of CDGI
manifested increased stereotypic behavior, and decreased distance
traveled, as judged both by video analysis (Figs. 6A and S6A,B,D,E) and
automated distance-traveled measurements (Figs. 6B and S6C,F,G)
relative to wildtype mice.
To determine whether amphetamine-induced stereotypies reflected
abnormal brain development arising from the loss of CDGI expression in
prenatal and early postnatal mice, we also tested mice from the mouse
line with a conditional, postnatal deletion of CDGI. As with mice having
a global CDGI knockout, the mice with the conditional CDGI knockout
responded to amphetamine treatment (7 mg/kg) with more focal ste
reotypies (Figs. S6H,I) and less ambulation than their wildtype litter
mates (Figs. S6J,K). The differential effects of amphetamine on the CDGI
knockout mice were not a consequence of alterations in amphetamine
pharmacokinetics (Fig. S6L) or DA metabolism (Fig. S4). This impact of
CDGI deletion on the response to amphetamine could reflect network
effects of CDGI absence; in particular, it is consistent with the require
ment for CDGI to have normal LTP in iSPNs, known to mediate move
ment suppression. M1R cholinergic signaling is also critical for cocaine
seeking. The effects of cocaine self-administration are negatively

regulated by striatal cholinergic signaling and M1Rs (Joseph and
Thomsen, 2017; Thomsen et al., 2010; Thomsen et al., 2012; Weikop
et al., 2020). We used a self-administration protocol (Thomsen et al.,
2005) to test for this effect, and asked whether or not M1R signaling
would suppress cocaine self-administration in CDGI knockout mice. As
expected, when wildtype mice were given the M1R allosteric agonist
VU0357017 by systemic injection, they self-administered less cocaine
than controls (Figs. 6C,D). In sharp contrast, in the CDGI knockouts, selfadministration of cocaine was unaffected by VU0357017 agonist treat
ment (Figs. 6C,D). When cocaine was replaced with saline in the selfadministration procedure, CDGI knockout mice extinguished nosepoking behavior normally (Figs. 6C,D). These findings are consistent
with the proposition that CDGI regulation of M1R signaling in iSPNs is
critical to the effects of psychomotor stimulants on behavior and drugseeking.
3. Discussion
Our findings demonstrate that CDGI plays a key role in dendritic
M1R-mediated modulation of iSPNs and exerts a profound effect on the
activity of neurons, circuits and behavior. Three observations led to this
conclusion. First, the deletion of CDGI selectively disrupted M1R-evoked
dendritic signaling in iSPNs, leaving somatic M1R-evoked signaling
intact. This deficit diminished iSPN synaptic integration and prevented
full induction of LTP at iSPN glutamatergic synapses. Second, CDGI
deletion impaired motor sequence and maze learning by the mice
7
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Fig. 6. CDGI knockout mice have heightened stereotypy response to amphetamine and fail to suppress cocaine self-administration in response to M1R activation. (A)
The proportion of time spent engaging in stereotypic sniffing, scored by videotape observation at 50–52 min post-injection, was higher in CDGI knockout (KO) mice
than in wildtype (WT) siblings after acute amphetamine (7 mg/kg). P value was calculated by two-tailed Mann-Whitney U test. Error bars show SEM. (B) In response
to high-dose amphetamine (7 mg/kg), KO mice engaged in less locomotion than WT mice, consistent with increased stereotypy. Dotted lines represent raw data from
each mouse; large open circles are population means; colored lines are random effects estimates of the median with 90% confidence intervals. Insets show sample
open-field tracker plots (50–55 min post-injection). See between group comparisons in Fig. S6C. (C) Both WT and KO mice self-administered cocaine dosedependently (cocaine dose, F(3,18) = 6.67, p = 0.003 and F(3,18) = 6.76, p = 0.003, respectively). The M1-selective agonist VU0357017 suppressed cocaine
self-administration in the WT mice only (treatment, F(1,6) = 9.52, p = 0.02; treatment-cocaine interaction F(3,18) = 9.29, p = 0.0006). **p < 0.01 and ***p < 0.001
vs. cocaine alone (repeated measures ANOVA and Bonferroni post-hoc test). (D) Examples of sessions from WT and KO mice showing each nose-poke (tick-marks) for
self-administration of cocaine (0.32 mg/kg/infusion), cocaine after VU0357017 treatment and saline after extinction of cocaine delivery. The numbers in parenthesis
correspond to the total number of reinforcers earned in the session. Numbers of mice tested are shown in panel keys.

without affecting the movements involved in the maze running and
without affecting out-of-task motor activities. Third, the CDGI knockout
mice exhibited increased stereotypic behaviors following administration
of the psychomotor stimulant, amphetamine, and they failed to be
rescued from cocaine self-administration by M1R agonist treatment, in
sharp contrast to their wildtype controls. These findings demonstrate
that CDGI is a potent regulator of cholinergic function in the striatum
mediated by indirect pathway-related circuits. The regulatory functions
of CDGI, affecting M1R muscarinic actions on iSPNs in the striatum,
affect behavioral balance across motor and psychomotor domains, and
affect cellular and behavioral features of striatal memory processing.
These functions of CDGI, together with its linkage to both HD and LID in
parkinsonian states and its relatively confined expression within the
striatum and adjacent olfactory structures, point to CDGI as a promising
therapeutic target.

indirectly. Much of this striatal circuitry involves the large extrastriosomal matrix compartment, which is viewed as the principal
sensorimotor and associative component of the striatum. The matrix
compartment contains most of the cell bodies of the cholinergic in
terneurons of the striatum and their local processes, and strongly ex
presses markers of cholinergic transmission, the attribute leading to
their discovery in the human striatum (Graybiel and Ragsdale, 1978).
M1Rs are robustly expressed by matrix iSPNs (Oldenburg and Ding,
2011), which, like dSPNs, express CDGI (Crittenden et al., 2010; Toki
et al., 2001). Proteins associated with cholinergic signaling (e.g., choline
acetyltransferase and acetylcholinesterase) are, like CDGI, matrixenriched (Graybiel et al., 1986; Graybiel and Ragsdale Jr., 1978).
Cholinergic innervation is derived largely from local cholinergic in
terneurons, but includes also cholinergic fibers originating in the
midbrain, including from the pedunculopontine nucleus (Dautan et al.,
2020; Dautan et al., 2014). Here we demonstrate that CDGI, itself
matrix-enriched, is critical to dendritic M1R signaling in iSPNs. We note
that the dendrites of the cholinergic interneurons are generally confined
to the matrix compartment, but their axons appear in both compart
ments, consistent with the idea that they could exert cross-compartment
effects (Crittenden et al., 2014). Thus, the effects of M1R signaling on
CDGI that we have found could be important for this cross-talk as well.
We were not able to differentiate striosomal and matrix iSPNs in our

3.1. CDGI transduction of M1R signaling is consistent with cholinergicrich features of the matrix compartment
The striatum is placed in a crucial position within the circuitry of the
basal ganglia, as it receives massive inputs from the neocortex and
thalamus and from aminergic neuromodulators including DA, and it in
turn can control the output nuclei of the basal ganglia either directly or
8
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experiments, and we emphasize that with our testing protocols, we
could not cover all possible cholinergic effects of CDGI deletion.
Nevertheless, our findings demonstrate a critical and multi-faceted
requirement for CDGI in the effects of cholinergic function in the stria
tum aimed at regulation of iSPNs via M1Rs.

induction in both iSPNs and dSPNs, was likely not a factor based on our
findings of normal DA release in the ex vivo brain slices from CDGI
knockout mice used to assess plasticity.
Our evidence showed clearly that CDGI deletion disrupted the full
induction of corticostriatal LTP in iSPNs. In wildtype iSPNs, pairing high
frequency stimulation of cortical inputs with postsynaptic depolariza
tion induced robust LTP in iSPNs. The induction of LTP was dependent
upon M1Rs, as antagonizing them with scopolamine blocked induction.
This M1R-dependence was not found in dSPNs, in which LTP induction
is negatively modulated by dendritic M4Rs (Shen et al., 2015) and un
affected by scopolamine.
The function of M1Rs in iSPN LTP induction is likely to be indirect.
By suppressing dendritic Kir2 K+ channels (and possibly other
depolarization-activated dendritic K+ channels), M1Rs enhance the
summation of the EPSPs evoked by high frequency stimulation and in
crease the depolarization of iSPN dendrites, allowing relief of the Mg2+
block of NMDA receptors, which together are necessary for LTP induc
tion in iSPNs (Calabresi et al., 1992a; Shen et al., 2008; Shen et al.,
2020). CDGI deletion disrupted the M1R suppression of dendritic Kir2
K+ channels in iSPNs and, in so doing, likely prevented adequate
engagement of NMDA receptors during the induction protocol. It should
be noted that the effect of M1R antagonism on LTP was stronger than
that of CDGI deletion. This result suggests that either M1R signaling has
effects on plasticity that are independent of CDGI (e.g., modulation of
somatic excitability) or that deletion leads to compensation. Unlike the
LTP induction in iSPNs, LTP induction in dSPNs required nominal
removal of extracellular Mg2+. The reason for this requirement is not
entirely clear, but this result is consistent with previous work (Calabresi
et al., 1992a) and the lower intrinsic excitability of dSPNs (Day et al.,
2008; Gertler et al., 2008). Established here is a framework for under
standing how CDGI shapes striatal plasticity and providing new insight
into the asymmetry of the cholinergic modulation of iSPNs and dSPNs
(Day et al., 2008; Shen et al., 2015; Shen et al., 2007).

3.2. CDGI mediates dendritic M1R signaling in iSPNs
CDGI activation by Ca2+ should be mediated by G-protein coupled
receptors (GPCRs) that activate phospholipase C (PLC) isoforms and
generate this second messenger (Rhee, 2001). Early work in nonneuronal cells suggested that the effects of M1R signaling, which acti
vates Gq /11 proteins and PLC, were CDGI-dependent (Guo et al., 2001;
Kawasaki et al., 1998). Remarkably, the M1R coupling to CDGI pre
dicted by this earlier work was found in the striatum. Deletion of CDGI
selectively disrupted the capacity of iSPN M1Rs to suppress the opening
of dendritic Kir2 K+ channels, which control the input impedance of
iSPN dendrites (Shen et al., 2020; Shen et al., 2007). Precisely how CDGI
deletion disrupted M1R modulation of Kir2 K+ channels remains to be
determined. It is known that PLC activation and depletion of membrane
PIP2 decreases Kir2 K+ opening (Hansen et al., 2011; Shen et al., 2007).
However, CDGI is thought to be downstream of this signaling event and
to be a positive modulator of Rap1 signaling, which in turn can regulate
Rac1 (Stefanini et al., 2012). Rac1 can down-regulate surface expression
of Kir2 K+ channels (Boyer et al., 2009), providing a complementary
mechanism to PIP2 depletion by which CDGI could be modulating
dendritic excitability. We found that the capacity for M1Rs to decrease
the opening of nominally somatic Kv7 K+ channels was unaffected by
CDGI deletion, suggesting that this modulation was likely to be solely
dependent upon membrane depletion of PIP2 (Hansen et al., 2011). PIP2
has been shown to bind to CDGI in some cell types (Sarker et al., 2020),
raising the possibility that depletion of PIP2 in the cell body blocks Ca2+mediated CDGI activation.
Unlike in iSPNs, measurements in dSPNs did not show significant
effects from CDGI deletion, despite clear evidence that dSPNs express
CDGI (Crittenden et al., 2010; Kawasaki et al., 1998; Toki et al., 2001).
In part, this difference is attributable to the subcellular distribution of
M1Rs in dSPNs. Although capable of modulating somatic excitability in
dSPNs, M1R signaling does not discernibly modulate dSPN dendritic
excitability (Day et al., 2008; Shen et al., 2007). The predominant
muscarinic receptor in dSPNs is the M4 muscarinic receptor (M4R),
which activates Gi/o proteins that inhibit dendritic D1 DA receptor
signaling and adenylyl cyclase activation (Shen et al., 2015). Additional
studies will be required to determine whether CDGI contributes to the
intracellular signaling of other Gq /11-coupled GPCRs known to be
expressed by dSPN dendrites, including type 1/5 metabotropic gluta
mate receptors (mGluR1/5) (Paquet and Smith, 2003).

3.4. CDGI shapes striatal learning and the response to psychomotor
stimulants
CDGI deletion produced clear, nuanced abnormalities in forms of
learning classically attributed to the striatum. Deletion of CDGI
impaired the ability to learn a simple T-maze task with egocentric cues.
CDGI deletion also impaired the ability to learn a complex-sequence
stepping task when somatosensory whisking cues were eliminated and
the mice were forced to rely only on motor memory or other informa
tion. These tests have been shown before to evoke strong and structured
repatterning of activity in the striatum of normal mice (Kitsukawa et al.,
2011). Striatal cholinergic signaling, particularly that mediated by
M1Rs, is itself pivotal for egocentric motor learning and behavioral
flexibility with changing reward contingencies (Bradfield et al., 2013; Lv
et al., 2017; McCool et al., 2008; Soares et al., 2013; Tzavos et al., 2004).
Thus, the behavioral deficits in CDGI deletion mutants are consistent
with the importance of CDGI transduction of striatal M1R signaling and
synaptic plasticity. CDGI signaling could be involved in other forms of
striatal learning and behavioral patterning that depend upon cholinergic
signaling, one possibility being adaptibility to change (Bradfield et al.,
2013; McCool et al., 2008).
CDGI-mediated modulation of iSPN dendritic excitability is un
doubtedly a critical factor in aspects of striatum-dependent learning, but
other processes likely are involved as well. One consequence of CDGIdeletion in mice that is likely to be relevant was the network suppres
sion of striatal DA release. Like ACh, DA figures prominently in most
forms of striatal synaptic plasticity (Gerfen and Surmeier, 2011). Deficits
in DA release diminish the vigor of movement (Panigrahi et al., 2015;
Schultz, 2019) and impair the acquisition of egocentric motor tasks
(Brasted et al., 1997; Braun et al., 2012). Long-term deficits in DA
release combined with normal levels of total DA in the CDGI knockout
mice could give rise to compensatory effects such as enhanced

3.3. CDGI is necessary for full induction of LTP in iSPNs
Plasticity at corticostriatal glutamatergic synapses on SPNs is
thought to underlie striatum-based learning and memory (Kreitzer and
Malenka, 2008; Yin and Knowlton, 2006). As in other regions of the
brain, both LTP and LTD can be induced at these glutamatergic synapses.
At least two forms of LTD have been described in SPNs (for review, see
(Zhai et al., 2018)). The most completely characterized one of these
(eCb-LTD) depends upon the activation of mGluR1/5 receptors and the
suppression of M1R signaling in iSPNs (Augustin et al., 2018; Gerdeman
et al., 2002; Kreitzer and Malenka, 2005; Shen et al., 2008; Wang et al.,
2006). Thus, CDGI deletion and disruption of M1R signaling should be
permissive for eCb-LTD. In accordance with this prediction, when we
examined eCb-LTD in SPNs from CDGI knockout mice by high frequency
stimulation of overlying cortex, we found it indistinguishable from that
in wildtype mice. M1R-dependent eCb-mediated synaptic plasticity at
inhibitory synapses onto SPNs (Narushima et al., 2007) was not exam
ined here. A direct alteration in DA signaling, which also can impact LTD
9
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behavioral responses to amphetamine. The mechanisms responsible for
the in vivo deficit in DA release following CDGI deletion are unclear. One
possibility is that the suppression of matrix iSPNs excitability by CDGI
deletion results in loss of collateral inhibition of neighboring dSPNs
(Taverna et al., 2008) and enhanced inhibition of DA-containing neu
rons through their projections to the substantia nigra. (Crittenden et al.,
2016; Evans et al., 2020; McGregor et al., 2019). Another possibility
related to network control is that elevated activity of neurons in the
external segment of the globus pallidus, a result of dampened iSPN
activation in CDGI knockouts, could lead to elevated inhibition of the
nigral dopaminergic neurons and reduced DA release (Evans et al., 2020;
Smith and Bolam, 1990; Watabe-Uchida et al., 2012). CDGI deletion in
dSPNs also could have important consequences for motor learning that
have yet to be discovered.
CDGI deletion clearly increased the idiosyncratic and focused ste
reotypies evoked by psychomotor stimulant administration. This
observation is also consistent with the well-described contribution of
cholinergic signaling in regulating stereotypies (Aliane et al., 2011;
Crittenden et al., 2014; Janickova et al., 2017; Kuczenski and Segal,
1997, 2001). In addition, CDGI deletion abolished the normal capacity
of M1R agonists to reduce cocaine self-administration. These striking
effects are consistent with a suppressive effect of iSPNs and the indirect
pathway on unwanted movements or actions (Albin et al., 1989;
DeLong, 1990; Heinsbroek et al., 2017; Mink, 1996). Thus, our findings
point to CDGI as a key regulator of striatal networks engaged by psy
chomotor stimulants.
CDGI is expressed broadly in the prenatal rodent brain, and modestly
in brain regions outside the striatum in the adult, raising the possibility
that the phenotypes in global CDGI knockout mice could be owing to loss
of CDGI in cell types other than mature SPNs. We confirmed that this is
not the case for amphetamine-induced stereotypy. Conditional CDGIflox/
flox
Cre(+) mice in which CDGI expression was lost only after birth, and
maintained in the cerebral cortex, showed severe stereotypies relative to
CDGIflox/floxCre(− ) sibling control mice. Although other tests were per
formed only in global CDGI knockout mice, the findings are nevertheless
directly relevant to humans lacking CDGI expression (Canault et al.,
2014; Crittenden et al., 2019).

(Pisani et al., 2007). Moreover, basal ACh release is diminished in HD
models (Farrar et al., 2011). Thus, it is possible that the down-regulation
of CDGI in HD is a consequence of diminished cholinergic signaling.
However, it is also possible that cell autonomous down-regulation of
CDGI contributes not only to diminished iSPN excitability, but also to
the suppression of cholinergic synaptic markers. To sort out these pos
sibilities, cell-type-specific expression of zinc finger proteins targeting
mutant huntingtin (Carrillo-Reid et al., 2019; Zeitler et al., 2019) could
be used to dissect cell autonomous and non-autonomous drivers of the
CDGI down-regulation.
Another neurodegenerative disorder associated with CDGI dysregu
lation and altered striatal cholinergic signaling is Parkinson's disease.
The hypokinetic features of Parkinson's disease are generally attributed
to elevated iSPNs excitability following the loss of striatal DA release,
the reverse of the hypoactivity of iSPNs in HD. There are two welldescribed drivers of this shift: loss of inhibitory D2 DA receptor
signaling and enhancement of excitatory M1R signaling (Pisani et al.,
2007). Muscarinic receptor antagonists are effective in alleviating motor
symptoms of Parkinson's disease, but are not well tolerated because of
side-effects (Katzenschlager et al., 2003). CDGI could provide an
important alternative target for down-regulating striatal M1R signaling:
unlike M1Rs, neuronal CDGI is largely restricted to the striatum and
adjoining olfactory structures (Kawasaki et al., 1998), minimizing any
off-target effects of down-regulating its function in the brain.
In late-stage Parkinson's patients, LIDs diminish the quality of life,
and there are only marginally effective treatments for these complica
tions (Fabbrini et al., 2007). CDGI down-regulation in rodent models of
LID is positively correlated with the severity of the abnormal movements
(Crittenden et al., 2009). Again, it is unclear at this point whether this
change is compensatory or contributory to the network pathophysiology
underlying LID. But given that boosting iSPN excitability during the onstate diminishes LID (Alcacer et al., 2017), it is possible that the downregulation of CDGI (and iSPN excitability) is a cause of the hyperkinetic
features of LID. It is notable that a striosome-enriched paralog of CDGI,
CalDAG-GEFII (aka RasGRP), is strongly up-regulated in LID models;
moreover, the extent of this up-regulation is correlated with the severity
of LID (Crittenden et al., 2009). This pattern of dysregulation is
consistent with the hypothesis that an imbalance in the activity of matrix
and striosomal SPNs contributes to the excessive movement patterns in
LIDs (Graybiel et al., 2000).
Our findings collectively suggest that CDGI is a major signaling
molecule modulating striatal excitability and plasticity that underlies
motor learning and responses to abused psychomotor stimulants. These
key functions of CDGI are, we show, to a significant extent attributable
to its mediation of cholinergic M1R signaling in iSPNs. Down-regulation
of CDGI in iSPNs, which help suppress unwanted movement, can
contribute to the hyperkinetic features of early HD and LID. We
emphasize that in contrast to widely distributed M1Rs, the narrow
forebrain distribution of CDGI, with its strong enhancement in the
striatum, makes CDGI an attractive therapeutic candidate target for
boosting iSPN excitability in HD and LID. The work presented here
creates a platform for exploring this possibility through understanding
how CDGI shapes the activity of striatal neurons that profoundly affect
action, learning and decision-making in health and disease.

3.5. Translational implications
The identification of CDGI as an effector of M1R signaling in iSPNs
has strong implications for work on clinical disorders. Our data from
global and post-natal striatal deletion of CDGI are consistent with an
M1R-CDGI signaling cascade in the repression of extreme repetitive
behaviors and self-administration induced by psychomotor stimulants.
Intensive research to develop small molecules that target specific
muscarinic receptor subtypes such as M1R is motivated by preclinical
results from rodent models of psychiatric disorders including drug
addiction (Choy et al., 2016; Moran et al., 2019; Stoll et al., 2018).
However, side-effects from peripheral M1R targeting have proven to be
a major stumbling block in the advancement of this approach (Moran
et al., 2019). Therapeutic targeting of CDGI could potentially alleviate
this problem by providing a tissue-specific entrée to the M1R signaling
cascade.
The hyperkinetic features of early manifest HD have long been
attributed to the preferential dysfunction of iSPNs responsible for sup
pression of unwanted movement (Albin et al., 1989; Plotkin and Sur
meier, 2015; Shen et al., 2015). In mouse models of HD, the dendritic
excitability of iSPNs is depressed, and LTP at corticostriatal synapses is
impaired (Carrillo-Reid et al., 2019; Plotkin et al., 2014), mimicking the
impact of CDGI deletion. CDGI expression is severely down-regulated in
HD patients, potentially a compensatory effect (Crittenden et al., 2010;
Desplats et al., 2006; Kuhn et al., 2007; Luthi-Carter et al., 2002). But it
is not yet clear whether this down-regulation is a cause or consequence
of striatal pathophysiology. Striatal cholinergic interneurons are not lost
in HD, but proteins associated with ACh release are down-regulated

4. Materials and methods
4.1. Mouse maintenance
All experiments were approved by, and performed in strict accor
dance with, the Massachusetts Institute of Technology (MIT) Committee
on Animal Care, which is accredited by AAALAC International. Mice
were group-housed and maintained under a standard light/dark cycle
with free access to food and water except during food-reinforced
learning and memory experiments, in which cases mice were singlehoused. For the cocaine self-administration assay and the total
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biogenic amine and amino acid data, CDGI knockout and sibling control
mice were in a congenic C57BL/6 J genetic background. For the
amphetamine-response experiments, the global CDGI knockouts and
sibling controls were in a congenic 129S4 genetic background. Condi
tional CDGIflox/floxCre(+) knockout mice and CDGIflox/floxCre(− ) sibling
controls were generated from D1-YAC Cre(+) mice in a C57BL/6
background (gift of Thomas Lemberger) and CDGIflox/flox mice in a
129S4 background. For the slice physiology experiments with identified
dSPNs or iSPNs, the CDGI knockout mice in a C57BL/6 J background
were crossed to Drd1-tdTomato or Drd2-EGFP BAC transgenic mice
(Gong et al., 2003) in a C57BL/6 background. For all other experiments,
mice were in an isogenic 129S4 genetic background. Male mice were
used for all behavioral and slice physiology experiments, which were
initiated prior to the National Institutes of Health policy for the inclusion
of both sexes.

centrifuged at 16,000 X g for 10 min to pellet insoluble material. Protein
concentration of supernatants was determined by bicinchoninic acid
assays (Thermo Fisher Scientific). Proteins were resolved by SDS-PAGE
and transferred to PVDF membrane (Millipore) by electroblotting. Blots
were incubated overnight, at 4 ◦ C, with antibodies diluted in TBST [10
mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.05% Tween 20)] and 5% bovine
serum albumin. Blots were subsequently washed in TBST and incubated
with horseradish peroxidase-coupled secondary antibodies (Vector
Laboratories, Burlingame, CA) prior to immunodetection with Western
Lightening (PerkinElmer Inc.) according to the manufacturer's in
structions. Blots were subsequently incubated with anti-β-tubulin (Cell
Signaling Technology) to control for protein loading. Antibodies were
obtained from the following companies: total GluR1 receptor (Calbio
chem), total ERK1/2, phospho-ERK1/2, total JNK, phospho-JNK, total
P38, phospho P38, total DARPP-32 and phospho-DARPP-32 (Cell
Signaling Technology); GluR2 receptor, phosphor-Ser831 GluR1 recep
tor, mGluR1 receptor, mGluR5 receptor, M1-type muscarinic receptor,
D1-type and D2-type DA receptor (Chemicon); phosphor-Ser845 GluR1
receptor (Novus Biologicals); Rap1, Rap2, CalDAG-GEFII/RasGRP2
(Santa Cruz Biotechnology); phosphor-CREB (Rockland Immunochem
icals); and PSD95 (Upstate Biotechnologies).

4.2. Generation of CDGI knockout mice
The CDGI targeting construct was based on a 6.2 kb SacI restriction
fragment from the 129Sv/cJ7 mouse chromosome 19 BAC clone 7D23
(Guru et al., 1999) that was subcloned into Bluescript II KS+ plasmid
(Stratagene Inc). One loxP site was ligated to a HindIII site in intron 4
and a loxP-flanked fusion gene for hygromycin resistance, and thymi
dine kinase was ligated to an AflII site in intron 2. The targeting
construct was electroporated into J1 mouse embryonic stem (ES) cells
(gift of Prof. Rudolf Jaenisch) that were subsequently grown in
hygromycin to select for integration. Resistant ES cell clones were
screened for homologous integration by polymerase chain reaction
(PCR) and Southern blotting. Clonal populations were transiently
transfected with the Cre recombinase vector Pog231, and gancylcovir
was applied to select for loss of thymidine kinase. PCR was used to
identify deletion clones, two of which were injected into blastocysts by
the MIT Department of Comparative Medicine facility. Resulting
chimeric mice were crossed to C57BL/6 to test for germline transmission
by coat colour, and transmitting males were crossed to 129S4 mice to
establish the mutation in a background isogenic with the J1 ES cells.
Phenotypic analyses were always performed on sibling progeny from
pure 129S4 heterozygous mutant intercross matings. Constitutive CDGI
knockout mice were genotyped by PCR with the following three oligo
nucleotide primers: 5′ –aacagttcccaggctagagatagagagttcctcc–3′ , 5′ –acca
gactctaggccagaacctacc–3′ , and 5′ –agtgtgctgtggtgaaatgcagccattcc–3′ .
Wildtype mice yielded a 208 base pair product with the first two
primers, whereas the knockout yielded a 286 base pair product with the
second two primers. Conditional CDGI floxed mice were genotyped by
PCR with the two primers 5’–tctcagctagtccatttcccaactagcgagttgc–3′ and
5’–aacagttcccaggctagagatagagagttcctcc–3′ to yield a 650 bp product
from the floxed allele and a 594 bp product from the wildtype allele.

4.5. Immunolabeling
Mouse brain sections were prepared for immunolabeling as previ
ously described (Crittenden et al., 2021; Niemz et al., 2017). The sec
tions were incubated with rabbit polyclonal CDGI antiserum (Crittenden
et al., 2004) for approximately 12 h at 4 ◦ C and processed either for
immunohistochemistry with ABC amplification (Vector Laboratories)
and DAB detection with nickel enhancement or, in conjunction with
mouse anti-CalDAG-GEFII antiserum (SC-8430, Santa Cruz Biotech
nology), for immunofluorescence with secondary antibodies coupled to
ALEXA 564 and ALEXA 488 (Invitrogen). Fluorescent labeling of neu
rons expressing D1 and D2 DA receptors was detected with mCherry or
EGFP filter set in sections from Drd1a-tdTomato and Drd2-EGFP BAC
transgenic mice (Gong et al., 2003). Sections were mounted and cov
erslipped with Eukitt (Electron Microscopy Sciences) following immu
nohistochemistry, or with Vectashield mounting medium (Vector
Laboratories) for confocal detection of genetic fluorescent labeling. The
sections were viewed with Olympus BX61 and SZX7 microscopes fitted
with an Olympus DP70 camera.
4.6. Exon microarray
Striatal tissue was collected in parallel in three different experiments
from age-matched male CDGI knockout mice and sibling controls. After
dissection, samples were frozen on dry ice and then homogenized in
Trizol (Sigma-Aldrich), and total RNA was prepared according to man
ufacturer's instructions and previously described methods (CantutiCastelvetri et al., 2005). Equivalent amounts of RNA from each sample
were pooled according to genotype (n = 4 of each genotype pooled for
two experiments and n = 3 of each genotype pooled for one experiment)
and given to the MIT BioMicro center to prepare cDNA for hybridization
to the Affymetrix GeneChip® Mouse Exon 1.0 ST. The MIT Bioinfor
matics core facility used Affymetrix Expression Console software to
summarize and normalize data from the chips.

4.3. Reverse transcriptase polymerase chain reaction
Mouse brain RNA was prepared using the RNAeasy kit (Qiagen).
Reverse-transcriptase quantitative polymerase chain reaction (RT-PCR)
was performed using the ThermoScript RT-PCR kit (Invitrogen) with two
primers flanking the sites where loxP was inserted: 5′ –taatacgact
cactatagggaggctgagctggttcaagtg–3′ and 5′ –atttaggtgacactatagaactgccg
cttccacttgtagg–3′ .

4.7. Measurements of total and extracellular striatal DA, DOPAC and
HVA

4.4. Western blotting
For harvesting mouse striatal and cortical tissue, mice were deeply
anesthetized with pentobarbital (150 mg/kg by intraperitoneal injec
tion), and tissue was dissected on a cold plate prior to freezing in liquid
nitrogen and storage at − 80 ◦ C. Frozen samples from mice were ho
mogenized in ice-cold modified RIPA buffer (50 mM Tris pH 8.0, 150
mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1%
NaDeoxycholate) with complete protease inhibitor cocktail (Roche) and

For microdialysis, guide cannulae were implanted in the striatum
using stereotaxic surgery. After at least one week for post-surgical re
covery, the microdialysis probe (CMA/7 probe 1 mm, CMA Micro
dialysis, Sweden) was lowered into the guide cannula, and
microdialysates were collected on ice in perchloric acid (0.5 M) at 20min intervals at a rate of 1.5 μl/min. Samples collected for the first
11
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hour were discarded, and subsequently collected samples were imme
diately frozen and kept at − 80 ◦ C until high performance liquid chro
matography (HPLC) analysis.
For measurements of DA, 3,4-dihydroxyphenylacetic acid (DOPAC)
and homovanillic acid (HVA) to assess COMT activity, mice were
decapitated 50 min after saline or amphetamine injection, and the
striata were dissected on ice and kept at − 80 ◦ C until shipment to the
laboratory of Prof. Tim Maher (Massachusetts College of Pharmacy and
Health Sciences) for HPLC.
For HPLC analysis, microdialysates were injected unmodified, and
striatal tissues were homogenized in 0.2 M perchloric acid, 0.2 mM
disodium EDTA and 0.2 mM ascorbic acid. Samples were assayed for
DOPAC, DA and HVA by HPLC with the potential set at +300 mV with
respect to a palladium‑hydrogen reference electrode.

Amphetamine measurements were performed at NMS Labs (Willow
Grove, PA) using liquid chromatography followed by mass spectrometry
(LC/MS/MS). Serum aliquots of 50 or 100 μl were diluted to 200 μl with
human serum. The dilution was taken into consideration to calculate the
final concentrations. An internal standard (D5-Amphetamine) and 10%
trichloroacetic acid were added to each sample while mixing vigorously.
Samples were centrifuged, and 200 μl of supernatant from each sample
was transferred to autosampler vials for analysis. Samples were analyzed
using a Waters Quattro Premier tandem mass spectrometer instrument
with electrospray ionization, and a Waters Acquity Ultra Performance
LC with an Acquity UPLC HSS T3.1, 2.1 × 50 mm, and 1.8-μm analytical
column. Two ion transitions were monitored for amphetamine and the
internal standards to assure that there were no interferences. Each
analytical run was independently calibrated at concentrations of 5.0, 10,
20, 50, 200, 500 and 1000 ng amphetamine/ml. Controls were run at 30,
375 and 750 ng/ml. During method validation, this LC/MS/MS method
had between-run percent CV's of 6.03, 3.02 and 4.72% at 5.0, 30 and
750 ng/ml, respectively. Amphetamine eluted at approximately 3.5 min
and the internal standard co-eluted.

4.8. Measurements of striatal amino acids and biogenic amines
For measurements of total amino acids and biogenic amines, male
mice between 4 and 5 months of age (n = 11 wildtypes and 7 knockouts)
were sacrificed by cervical dislocation, and striatal tissue was dissected
and frozen on dry ice for shipment to the Vanderbilt Neurochemistry
core for HPLC measurements.

4.11. Open-field behavior, rotarod balance and fear conditioning
Horizontal and vertical locomotor activity (distance traveled, rear
ing) for the evaluation of open-field activity and fear-conditioning tasks
was collected via the TruScan System (activity boxes surrounded by 2
rings fitted with infrared sensors, Coulbourn Instrument, Allentown,
USA). The same system was used to measure ‘time spent in the margin’
(thigmotaxis) and ‘number of center entries’ for the assessment of
anxiety-related behaviors. For fear-conditioning procedures, mice
received 5 tones paired with foot shocks (1 per min) in box A after 2 min
of free exploration (baseline A) on day 1. On the morning of the
following day, mice were placed in the same box without tone or foot
shock for 3 min. In the afternoon of the same day, mice were placed in
box B (contextually different), and the tone alone was delivered for 3
min after 2 min free exploration of the new box (baseline B). Percent
decrease in distance traveled versus baseline in either box was calculated
as a measure of association of foot shocks with context or foot shocks
with cue. To evaluate motor coordination, mice were placed individu
ally onto an elevated rod accelerating from 4 to 40 rpm over 10 min
(Columbus Instruments), and latency to fall was measured.

4.9. DA receptor autoradiography
D1- and D2-type DA receptor autoradiography was performed as
described in Unterwald et al. (Unterwald et al., 1994; Unterwald et al.,
2001). D3 receptor autoradiography was carried out according to the
method described by Guitart-Masip et al. (Guitart-Masip et al., 2006).
Mouse brains were stored at − 80 ◦ C prior to dissection. Mouse brains
were mounted on cryostat chucks using embedding matrix, cut on a
Reichert and Jung 2800 Frigocut N into 16 μm coronal sections based on
the Paxinos and Franklin mouse brain atlas (Paxinos and Franklin,
2001), thaw-mounted onto Fisher superfrost glass slides, air-dried on ice
and stored desiccated at − 30 ◦ C until assayed. Slide-mounted sections
were preincubated in buffer containing 50 mM Tris HCl, 120 mM NaCl,
5 mM KCl, 2 mM CaCl2 and 1 mM MgCl2, pH 7.4, at room temperature
for 30 min. Following preincubation, sections were incubated for 45 min
at room temperature in the same Tris-salt buffer in the presence of 1 μM
mianserin and 5 nM 3H-SCH23390, without and with 10 μM fluphen
azine to measure, respectively, total and nonspecific binding for the D1type DA receptor. For D2-type receptor autoradiography, slides were
incubated in the preincubation buffer with 0.001% ascorbic acid, 1 μM
mianserin and 5 nM 3H-raclopride without and with 10 μM (+)buta
clamol to measure total and nonspecific binding, respectively. For D3
receptor binding, slides were incubated in the preincubation buffer in
the presence of 0.001% ascorbic acid, 5 nM 3H-PD128907 without and
with 1 μM (+)butaclamol to measure total and nonspecific binding,
respectively. After incubation, slides were washed twice in the Tris-salt
buffer on ice for 5 min/wash followed by rinse in ice-cold distilled water.
Sections were dried under a cold air stream and allowed to sit overnight
at room temperature. Slides for DA receptor autoradiography and
tritium standards (Amersham) were exposed to tritium-sensitive film for
7 weeks (D1 receptor), 13 weeks (D2 receptor) or 23 weeks (D3 recep
tor). Receptor densities were determined by measuring the optical
densities of brain regions of interest and by comparing them to the
standard curve generated by the tritium standards exposed to the same
sheet of film (MCID System, Imaging Research Inc., Cambridge, UK).
Differences in mean receptor density values between genotypes were
analyzed by an unpaired two-tailed Students t-test.

4.12. Home cage scan
Male wildtype and knockout brothers, 6–7 months of age were
single-housed for >7 days prior to videoscanning. Lights were out from
7 pm to 7 am, and videotaping occurred from 6 pm to 6 am. Data were
analyzed by user-trained CleverSys software as described previously
(Steele et al., 2007).
4.13. Social interaction and memory test
According to the method described previously (Crawley, 2000),
single-housed male mice were placed individually into a large cage with
bedding and two small metal wire enclosures inside, and were allowed
to acclimate for 20 min. The male was then removed, and an ovariec
tomized female was placed into the small wire cage prior to returning
the male. The male was videotaped for 2 min prior to removal of the
female mouse. After 20 min, the same female was re-introduced for 2
min, and this procedure was repeated four times in total prior to intro
ducing a novel ovariectomized female. Videotapes were scored, and the
amount of time that the male had nose-contact with the cage containing
the female was plotted.

4.10. Measurements of serum amphetamine

4.14. Olfactory acuity test

For serum amphetamine measurements, blood was collected into
serum separation tubes (Starstedt AG & Co.) by retro-orbital bleeds from
mice under isofluorane anesthesia, 50 min after amphetamine injection.

Wildtype and brother knockout male mice were co-housed and food12
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restricted by being given access to food for only one hour per day, plus
sucrose pellets sprinkled in their home cage (BioServ). Mice were
trained for two days by placing them individually into a clean cage in the
morning and, in the afternoon, were given 15 sucrose pellets on top and
beneath the bedding. On the following test day, each mouse went
through five trials in which it was removed from the cage, a single pellet
was buried, and measurements were taken of the time for the mouse to
find the pellet after reintroduction to the cage.

4.18. Amphetamine treatments
Different groups of male mice (6–10 months old) were used for each
drug treatment. All experiments were conducted genotype-blind. Mice
were habituated to injection for 3–5 days and placed in TruScan activity
monitors for at least 20 min prior to drug injection. D-amphetamine
(Sigma-Aldrich) was dissolved in saline and administered at 10 ml/kg
body weight intraperitoneally. Distance traveled was computed by
infrared photobeam breaks, sampled every 0.5 s. Stereotypies were
measured from 2 min videotapes made at 50 min post-injection (peakstereotypy response period) and rated with a keypad scoring system by a
rater blinded to genotype as previously described (Crittenden et al.,
2014). Distance-traveled data were analyzed by a state-space model
(Kitagawa and Gersch, 1996; Smith et al., 2004). Activity monitor data
for distance-traveled were chosen for 21 time-points (− 15 to 85 min in
steps of 5 min) for all wildtype and CDGI knockout mice described in
detail (with computer code for this application) previously (Crittenden
et al., 2019). Briefly, the model provided a population estimate for the
distance-traveled across 21 time-points (− 15 to 85 min in steps of 5 min)
for the wildtype and CDGI knockout groups. Group population estimates
were compared using Monte Carlo techniques with between group dif
ferences highlighted where p < 0.05.

4.15. Marble burying
Based on a method described previously (Thomas et al., 2009), male
mice were placed into a clean cage and given 30 min to habituate. The
mouse was removed, and 9 clean marbles were placed, evenly-spaced,
on top of the bedding. The mouse was returned to the cage and video
taped for 15 min. The number of marbles visible at the end was reported
as an average across trials. Mice were given three trials across three
days.
4.16. Egocentric and allocentric T-maze tasks
Training was done by an experimenter blinded to genotype, and mice
were in mixed-genotype groups. Egocentric T-maze training was con
ducted in an acrylic cross-shaped maze with white floor and transparent
walls. Different departure arms were used so that mice learned to
associate the rewarded arm with egocentric cues rather than distal cues.
Male mice, food-restricted to reach 85% of their free-feeding weight,
were given 3–5 habituation sessions in which they were allowed to move
freely in the two T-maze configurations and to consume chocolate milk
placed at the end of the goal arms. Mice were rewarded with chocolate
milk for turning in a consistent direction (left vs. right), regardless of
their start site and the spatial cues. The rewarded direction was
randomly assigned at the beginning of the training unless the mouse had
developed a turning bias during the habituation, in which case the
opposite direction was baited with food-reward for the training. Each
mouse received 10 trials (5 trials from each of 2 start sites), with an
inter-trial interval of 30–120 s, during each daily session for 10 days.
Allocentric T-maze training was conducted in a water maze filled
with white dyed water (21 ◦ C) into which a mouse was placed at the base
of the T to begin the trial. The trial was ended when the mouse touched
both forepaws to the submerged escape platform (correct choice) or
reached the extremity of the other branch of the T (incorrect choice).
The platform was located at a constant position in the experimental
room, and extra-maze visual cues were provided to instruct the mice of
the platform location. Start arms were varied to avert the use of
egocentric cues. Percent correct choices and latency to reach one ex
tremity of the T (data not shown) were recorded. Each mouse received
10 trials per day.

4.19. Cocaine intravenous self-administration
All procedures were approved by the McLean Hospital Institutional
Animal Care and Use Committee. Mice were trained and tested as pre
viously described under an FR 1 schedule of reinforcement in daily 3 h
sessions, 5–6 days/week (Thomsen et al., 2010). VU0357017 was syn
thesized at Vanderbilt University (Lebois et al., 2010), dissolved in
sterile water (made fresh daily) and administered subcutaneously at 5.6
mg/kg, 15 min before the test session.
4.20. Fast-scan cyclic voltammetry
All voltammetric experiments were approved and performed in strict
accordance with the Institute of Comparative Medicine Laboratory An
imal Resources at Columbia University.
Striatal DA release was studied in two to five month old male
knockout and wildtype mice. Recordings were obtained from the stria
tum in the first three most rostral coronal slices (300 μm). Three sites in
the dorsal striatal region of each slice were measured and averaged.
Slices were allowed to recover for 1.5 h in a holding chamber in
oxygenated artificial cerebrospinal fluid (ACSF) at room temperature,
and then were placed in a recording chamber and superfused (1 ml/min)
with ACSF (in mM: NaCl 125, KCl 2.5, NaHCO3 26, CaCl2 2.4, MgSO4
1.3, KH2PO4 0.3, glucose 10) at 36 ◦ C.
As described previously (Zhang and Sulzer, 2003), disk carbon fiber
electrodes of 5 μm diameter with a freshly cut surface were placed into
the dorsal striatum about 50 μm into the slice. For cyclic voltammetry, a
triangular voltage wave (− 400 to +900 mV at 280 V/s versus Ag/AgCl)
was applied to the electrode every 100 ms. Current was recorded with an
Axopatch 200B amplifier (Axon Instrument, San Jose, CA), with a lowpass Bessel Filter setting at 10 kHz, digitized at 25 kHz (ITC-18 board,
InstruTech Corporation). Triangular wave generation and data acquisi
tion were controlled by a computer running a house-written IGOR
program (WaveMetrics). Striatal slices were electrically stimulated
every 2 min with either a single pulse stimulation or a paired stimulus by
an Iso-Flex stimulus isolator triggered by a Master-8 pulse generator (A.
M.P.I.) using a bipolar stimulating electrode placed ~100 μm from the
recording electrode. Background-subtracted cyclic voltammograms
served to identify the released substance. The DA oxidation current was
converted to concentration based upon a calibration of 5 μM DA in ACSF
after the experiment.

4.17. Step-wheel training
All procedures were approved and in accordance with guidelines for
the conduct of animal research of Osaka University. The investigator
training the mice was blinded to their genotypes. As previously
described (Kitsukawa et al., 2011), mice were water-restricted and
habituated to run on a step-wheel with moveable pegs in order to reach a
water spout. Contact of the paw on the last (12th) rung was detected by a
voltage change. Mice were trained for 6 days with a regularly spaced
rung-pattern followed by 7 days of training with irregularly spaced rung
pattern 1, followed by 3 days of training with irregularly spaced rung
pattern 2. The whiskers of all mice were then cut off, and the mice were
given 2 days in their home cage followed by re-testing for 8 days with
irregularly spaced rung pattern 1. The variance of paw-touch to the 12th
rung across training was calculated (Nakamura et al., 2017).
13
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4.21. Corticostriatal LTD induction
Experiments were approved and performed in strict accordance with
the procedures put forward by the Italian Health Ministry. Cortico
striatal EPSPs were evoked by a stimulating electrode placed in cortical
regions close to the recording electrode. Bicuculline (10 μM) was added
to ~50% of the experiments to test for contamination of the EPSPs by
GABAA receptor-mediated depolarization. The addition of bicuculline
did not have an effect on EPSPs, thus data obtained with and without the
drug were pooled. For HFS, 3 stimulus trains were applied (3 s duration,
100 Hz frequency, 20 s intervals). HFS protocol was delivered in the
presence of 1.2 mM external magnesium to optimize the appearance of
LTD.

5% isofluorane during induction and 2% isofluorane during mainte
nance phase) and positioned in a stereotaxic frame (David Kopf In
struments, Tujunga, CA). Mice were administered with analgesics
meloxicam (METACAM®, 0.1 mg/kg, s.c., Covetrus) before surgery.
After the skin and fascia were retracted to reveal the skull, a small hole
was drilled, and an injection needle was slowly inserted into the stria
tum. The viral vector (AAV9-hSyn-iAChSnFR, 800 nl, titer: 8–10 × 1012,
a generous gift of Looger lab (Borden et al., 2020)) was slowly infused at
the following coordinates (in mm): AP 1, ML ±2 and DV − 3 relative to
Bregma. The injection needle was left in place for 5 min to allow tissue
absorption of the virus, and then withdrawn. The mice were then su
tured and placed on a heating pad until recovery from anesthesia. Im
aging experiments were performed 3–5 weeks after viral injection.

4.22. Slice electrophysiology in identified D1 and D2 SPNs

4.24. Two-photon laser-scanning microscopy (2PLSM)

Animal use procedures were reviewed and approved by the North
western Institutional Animal Care and Use Committee. CDGI knockout
mice expressing one copy of tdTomato or EGFP under control of Drd1a
or Drd2 receptor regulator elements were used for cell type-specific
physiological studies at 8–12 weeks of age. Mice were deeply anes
thetized with a mixture of ketamine (100 mg/kg) and xylazine (7 mg/
kg) and perfused transcardially with ice-cold sucrose-based cutting so
lution containing (in mM): 181 sucrose, 25 NaHCO3, 1.25 NaH2PO4, 2.5
KCl, 0.5 CaCl2, 7 MgCl2, 11.6 sodium ascorbate, 3.1 sodium pyruvate
and 5 glucose (305 mOsm/l). Parasagittal slices (280-μm thick) were
sectioned using a vibrotome (Leica VT1200). After cutting, slices were
incubated at 34 ◦ C for 40 min in ACSF containing (in mM): 124 NaCl, 3
KCl, 1 NaH2PO4, 2.0 CaCl2, 1.0 MgCl2, 26 NaHCO3 and 13.89 glucose,
after which they were stored at room temperature until recording.
External solutions were oxygenated with carbogen (95%CO2/5%O2) at
all time.
Individual slices were transferred to a recording chamber and
continuously superfused with ACSF (2–3 ml/min, 30–32 ◦ C). Gabazine
(10 μM) was added in the bath to block GABAA receptors. Whole-cell
current clamp recordings were obtained from dSPNs or iSPNs in the
dorsolateral striatum identified by their fluorescence. Patch pipettes
(3–4 MΩ resistance) were loaded with internal solution containing
(mM): 115 K-gluconate, 20 KCl, 1.5 MgCl2, 5 HEPES, 0.2 EGTA, 2 MgATP, 0.5 Na-GTP, 10 Na-phosphocreatine (pH 7.25, osmolarity
280–290 mOsm/l). The only exception was Mg2+-free LTP experiments
in which ACSF contained nominal zero Mg2+ and Mg-ATP in pipette
solution was replaced by Na-ATP. All the recordings were made using a
MultiClamp 700B amplifier (Axon Instrument, USA), and signals were
filtered at 2 kHz and digitized at 10 kHz. Stimulation and data acqui
sition were performed with PraireView5.
Corticostriatal EPSPs (2–8 mV) were evoked by a parallel bipolar
electrode (0.2 ms) placed in deeper layers of the cortex. To assess syn
aptic summation, a train of five stimuli (40 Hz) was delivered every 20 s.
To assess somatic excitability, gabazine was omitted from ACSF. Cur
rents of increasing amplitudes (20–300 pA, 500 ms) were injected, and
the number of evoked somatic action potentials was measured. To
induce LTP in normal ACSF, HFS (100 Hz for 1 s) was paired with cur
rent injection (1–2 nA, 1 s), which was repeated four times with 20 s
intervals. To induce LTP in Mg2+-free condition, Mg2+ was omitted from
ACSF and pipette solution, and LTP was induced in dSPNs by three trains
of HFS (100 Hz for 1 s) with 20-s intervals (Calabresi et al., 1992a).
Data analysis was conducted with custom scripts written in Python 3
(available upon request) and Prism 6. Non-parametric Wilcoxon or
Mann-Whitney tests were used, and a P value less than 0.05 was
considered statistically significant.

ACh release was assessed by imaging iAChSnFR (Borden et al.,
2020), a genetically encoded fluorescent sensor of ACh (pAAV.hSynap.
iAChSnFR was a gift from Loren Looger (Addgene plasmid #137950;
http://n2t.net/addgene:137950; RRID: Addgene_137,950)), using
2PLSM. Acute parasagittal slices with striatal expression of iAChSnFR
were prepared as described above, transferred to a recording chamber,
and continuously perfused with normal ACSF at 32–34 ◦ C. A two-photon
laser (Chameleon Ultra II, Coherent, Santa Clara, CA) tuned to 920 nm
was used to excite iAChSnFR. Fluorescence was imaged using an Ultima
Laser Scanning Microscope system (Bruker, Billerica, MA) with an
Olympus 60×/0.9 NA water-immersion objective lens and a Hamamatsu
H7422P-40 GaAsP PMT (490 nm to 560 nm, Hamamatsu Photonics,
Hamamatsu, Japan). Time series images of iAChSnFR were acquired
with 0.388 μm × 0.388 μm pixels, 4-μs dwell time and a frame rate of
2.754 fps. After 30-s baseline acquisition, synchronous ACh release was
evoked by delivering a train of 20 electrical stimuli (1 ms × 50 μA, at 2
Hz and 20 Hz) by a concentric bipolar electrode (FHC, Bowdoin, ME)
placed at 200 μm ventral to the region of interest. Imaging was
continued for at least another minute. Two trials were performed for
each stimulation protocol. The dynamic range of the optical probe was
determined by applying 10 μM cadmium chloride (to block any basal
transmission) and 100 μM acetylcholine chloride (to saturate iAChSnFR
signal) for determining minimal (Fmin) and maximal fluorescence in
tensity (Fmax). Because our preliminary data indicated that cadmium
did not change basal fluorescence, we concluded that basal ACh level in
acute slices is undetectable by iAChSnFR, and therefore cadmium
chloride application was omitted. Fluorescent intensity data were
analyzed by custom Python code (available upon request). Briefly, the
fluorescence intensity values were first background-subtracted (the
background resulted from PMT was measured by imaging with same
PMT voltage but zero laser power) and averaged over two trials. Base
line fluorescence F0 was the mean fluorescence over the 10 s right before
stimulation and ΔF/(Fmax − Fmin) was quantified and presented.
4.25. Confocal microscopy of CDGI knockouts crossed to transgenic
reporter lines
Anesthetized CDGI knockout mice crossed with reporter lines (D1tdTomato x CDGI knockouts or D2-EGFP x CDGI knockouts) were
perfused transcardially with saline briefly (~1 min) and then with icecold 4% paraformaldehyde (wt/vol) in 1× phosphate buffered saline
(4% PFA-PBS). Brains were dissected out and incubated in 4% PFA-PBS
overnight at 4 ◦ C. Sagittal slices (100-μm thick) were cut using a Leica
vibratome (VT1200S, Leica Biosystems, Wetzlar, Germany), mounted
with Vectashield (Vector Laboratories), and viewed under a laser scan
ning confocal microscope (FV10i; Olympus). Images were adjusted for
brightness, contrast and pseudo-coloring in ImageJ (US National In
stitutes of Health).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.nbd.2021.105473.

4.23. Stereotaxic viral injection
Wildtype and CDGI knockout mice (8–12 weeks old, male) were
anesthetized using an isoflurane precision vaporizer (Kent Scientific, at
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